The development of therapies for central nervous system (CNS) disorders remains challenging because most drugs cannot efficiently cross the blood-brain barrier (BBB). The BBB protects the brain from harmful substances but also limits the delivery of potentially beneficial therapeutics. Intranasal drug delivery has emerged as an attractive non-invasive strategy because drugs administered through the nasal cavity can bypass the BBB and reach the brain directly through neural pathways. This approach has gained increasing attention for the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, glioblastoma, and other neurological disorders.

Figure 2. Nose-to-Brain Drug Delivery Pathways

The nasal cavity contains several specialized cell populations that contribute to direct brain delivery.

Olfactory sensory neurons are located in the olfactory epithelium of the upper nasal cavity. These bipolar neurons possess:

• Dendrites extending into the nasal mucus layer
• Axons projecting directly through the cribriform plate
• Synaptic connections within the olfactory bulb

Because these neurons establish a direct anatomical connection between the external environment and the brain, they represent one of the most important pathways for nose-to-brain drug transport.

Sustentacular cells support olfactory neurons by:

• Maintaining epithelial integrity
• Regulating ionic balance
• Participating in xenobiotic metabolism
• Supporting neuronal regeneration

These cells influence drug absorption and local inflammatory responses.

Basal cells serve as progenitor cells capable of regenerating olfactory neurons throughout life.

Two major populations include:

• Horizontal basal cells
• Globose basal cells

Their regenerative capacity contributes to maintaining long-term functionality of the olfactory pathway.

The trigeminal nerve innervates both respiratory and olfactory regions of the nasal cavity.

Drug molecules can travel through:

• Ophthalmic branch (V1)
• Maxillary branch (V2)

and subsequently reach:

• Brainstem
• Pons
• Cerebellum
• Various forebrain regions

This pathway complements olfactory transport and expands brain distribution.

Respiratory epithelial cells represent the largest surface area in the nasal cavity.

They facilitate:

• Transcellular transport
• Paracellular transport
• Endocytosis-mediated uptake

Nanoparticles and biologics frequently utilize these mechanisms.

Several transport mechanisms have been identified:

Drug molecules enter neurons and move along axons via microtubule-dependent transport.

Advantages:

• Highly targeted delivery
• Potential long-term retention

Limitations:

• Relatively slow transport rate

Drugs diffuse along:

• Perineural spaces
• Perivascular channels
• Cerebrospinal fluid pathways

Advantages:

• Rapid delivery
• Broad brain distribution

This mechanism is believed to account for much of the early drug appearance within the brain.

Recent studies suggest that nasal administration can access:

• Meningeal lymphatic vessels
• Glymphatic clearance systems

These pathways may facilitate widespread CNS distribution.

Several compounds are being investigated for Alzheimer's disease:

Intranasal insulin has demonstrated:

• Improved memory performance
• Enhanced cognitive function
• Increased neuronal glucose utilization

without significant systemic hypoglycemia.

Intranasal delivery of:

• Exenatide
• Liraglutide
• Semaglutide derivatives

is being explored to reduce:

• Neuroinflammation
• Tau pathology
• Amyloid accumulation

Investigational intranasal therapies include:

• Dopamine formulations
• Levodopa nanoparticles
• Neurotrophic factors
• Gene therapies

The goal is to improve CNS drug levels while minimizing peripheral side effects.

For glioblastoma and other brain cancers, intranasal delivery of:

• Chemotherapeutics
• siRNA
• Antibodies
• Nanoparticle formulations

has demonstrated enhanced brain penetration in preclinical studies.

Large biologics traditionally unable to cross the BBB are being developed for intranasal administration, including:

• BDNF (Brain-Derived Neurotrophic Factor)
• NGF (Nerve Growth Factor)
• Monoclonal antibodies
• Anti-inflammatory proteins

Modern formulations increasingly employ nanotechnology.

Advantages include:

• Improved stability
• Enhanced mucosal penetration
• Controlled drug release

Common materials:

• Chitosan
• PLGA
• PEGylated polymers

These systems improve residence time within the nasal cavity.

Exosomes are emerging as natural nanocarriers capable of:

• Crossing biological barriers
• Delivering RNA and proteins
• Targeting neurons and glial cells

If SAC-derived calcium ions can be efficiently delivered through intranasal pathways, several theoretical mechanisms may be relevant:

1. Modulation of neuronal calcium homeostasis.
2. Regulation of astrocyte and microglial inflammatory responses.
3. Reduction of IL-6, TNF-α, MMPs, and other neuroinflammatory mediators.
4. Potential normalization of aberrant CaSR signaling.
5. Protection against pathological tau hyperphosphorylation through improved cellular calcium regulation.
6. Support of mitochondrial bioenergetics and neuronal survival.

However, these potential effects remain hypothetical until validated through:

• Cell culture studies
• BBB and nasal transport models
• Alzheimer's animal models
• Pharmacokinetic studies
• Clinical investigations

Intranasal drug delivery has emerged as one of the most promising strategies for bypassing the blood-brain barrier and directly targeting the central nervous system. Olfactory neurons, trigeminal nerve pathways, and specialized nasal epithelial cells provide unique routes through which therapeutic agents can reach the brain. Current development efforts focus on neurodegenerative diseases, brain tumors, peptides, biologics, and nanoparticle-based formulations. Future research may also explore novel calcium-based therapeutics, including SAC-derived compounds, as potential modulators of neuroinflammation and neuronal calcium signaling in Alzheimer's disease and related disorders.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, amyloid-β (Aβ) accumulation, tau hyperphosphorylation, synaptic dysfunction, and chronic neuroinflammation. Increasing evidence suggests that neuroinflammation mediated by activated astrocytes and microglia plays a central role in disease progression. Sigma Anti-Bonding Calcium Carbonate (SAC), a highly bioavailable calcium ion-generating compound, has demonstrated anti-inflammatory properties, including suppression of interleukin-6 (IL-6) and matrix metalloproteinases (MMPs). These biological activities suggest that SAC may offer a novel therapeutic strategy for Alzheimer's disease by modulating neuroinflammatory pathways and restoring neuronal homeostasis.

Traditionally, Alzheimer's disease has been viewed as a disorder driven by amyloid plaques and neurofibrillary tangles. However, recent studies indicate that chronic neuroinflammation is a critical contributor to neuronal degeneration.

In the AD brain, amyloid-β oligomers activate astrocytes and microglia, leading to the release of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6. Persistent activation of these pathways promotes oxidative stress, synaptic loss, mitochondrial dysfunction, and neuronal death. Among these inflammatory mediators, IL-6 is particularly important because it activates the JAK/STAT3 signaling pathway, which has been implicated in tau hyperphosphorylation and disease progression.

Elevated IL-6 levels have been consistently observed in the cerebrospinal fluid and brain tissue of Alzheimer's patients and correlate with cognitive impairment. Therefore, suppression of IL-6-mediated neuroinflammation represents an attractive therapeutic target.

Figure 3. Proposed Modulation of Neuroinflammation

Recent experimental observations indicate that SAC significantly reduces IL-6 production in various cellular systems. If these findings are confirmed in neural tissues, SAC could interrupt the inflammatory cascade associated with Alzheimer's disease.

By suppressing IL-6 production, SAC may attenuate STAT3 signaling and subsequently reduce tau pathology and neurodegeneration.

Furthermore, SAC may contribute to stabilization of intracellular calcium homeostasis. Dysregulated calcium signaling is a hallmark of Alzheimer's disease and contributes to excessive activation of calcium-dependent kinases such as CaMKII, CDK5, and GSK-3β, all of which promote tau phosphorylation. Restoration of physiological calcium regulation could therefore provide an additional neuroprotective mechanism.

Another important observation is the ability of SAC to reduce matrix metalloproteinase (MMP) expression.

MMP-2 and MMP-9 are involved in degradation of extracellular matrix proteins and disruption of the blood-brain barrier (BBB). Elevated MMP activity has been reported in Alzheimer's disease and is associated with:

• BBB breakdown
• Increased neuroinflammation
• Leukocyte infiltration
• Accelerated neuronal injury

Suppression of MMP activity by SAC may therefore preserve BBB integrity and reduce inflammatory cell recruitment into the central nervous system.

Intranasal administration offers a promising route for delivering SAC directly to the central nervous system while bypassing the blood-brain barrier. Molecules administered through the nasal cavity can reach the brain via olfactory and trigeminal neural pathways.

This approach may allow higher local concentrations within brain tissue while minimizing systemic exposure. If SAC can effectively reach astrocytes and neurons through intranasal delivery, it may provide a practical strategy for long-term neuroprotection.

To evaluate the therapeutic potential of SAC in Alzheimer's disease, future studies should investigate:

1. Effects on astrocyte and microglial activation.
2. Changes in IL-6, TNF-α, and other inflammatory cytokines.
3. Modulation of tau phosphorylation pathways.
4. Effects on MMP-2 and MMP-9 expression.
5. Restoration of neuronal calcium homeostasis.
6. Cognitive outcomes in APP/PS1 and 3xTg-AD animal models.
7. Brain biodistribution following intranasal administration.

The anti-inflammatory properties of SAC, particularly its ability to suppress IL-6 and MMP expression, suggest a novel therapeutic opportunity for Alzheimer's disease. Rather than directly targeting amyloid deposition, SAC may act by modulating the neuroinflammatory microenvironment, stabilizing calcium homeostasis, protecting blood-brain barrier integrity, and reducing tau-associated neurodegeneration. Although further mechanistic and preclinical studies are required, SAC represents a promising candidate for the development of next-generation neuroprotective interventions in Alzheimer's disease.

Neuroinflammation is increasingly recognized as a central contributor to cognitive decline, aging-related neurodegeneration, and Alzheimer's disease. Elevated levels of inflammatory mediators such as interleukin-6 (IL-6) and matrix metalloproteinases (MMPs) contribute to neuronal dysfunction, blood-brain barrier disruption, synaptic loss, and impaired memory formation. Sigma Anti-Bonding Calcium Carbonate (SAC), a highly bioavailable calcium formulation, has demonstrated the ability to reduce cellular IL-6 and MMP expression in experimental systems. Because intranasal administration provides a direct route to the central nervous system through olfactory and trigeminal pathways, SAC nasal spray may represent a novel strategy for modulating neuroinflammation and supporting cognitive function. This article discusses the potential mechanisms through which intranasal SAC could improve memory and cognition.

Alzheimer's disease and age-related cognitive decline are characterized by chronic neuroinflammation, oxidative stress, mitochondrial dysfunction, abnormal protein phosphorylation, and progressive neuronal loss. Among inflammatory mediators implicated in these processes, IL-6 and MMPs play particularly important roles.

Elevated IL-6 levels are associated with:

• Increased microglial activation
• Synaptic dysfunction
• Reduced neuroplasticity
• Accelerated cognitive decline

Similarly, increased MMP activity contributes to:

• Blood-brain barrier disruption
• Neurovascular dysfunction
• Neuroinflammation
• Progressive neuronal damage

Consequently, therapeutic approaches capable of reducing IL-6 and MMP activity may help preserve neuronal health and cognitive performance.

The blood-brain barrier significantly limits the delivery of many therapeutic compounds to the central nervous system. Intranasal administration offers a non-invasive alternative that bypasses the BBB through:

1. Olfactory neuronal pathways
2. Trigeminal nerve pathways
3. Perineural extracellular transport routes

Drugs delivered intranasally can reach:

• Olfactory bulb
• Frontal cortex
• Hippocampus
• Brainstem
• Cerebral cortex

within a relatively short period of time.

Because the hippocampus plays a central role in learning and memory, intranasal delivery has become an attractive strategy for cognitive enhancement and neuroprotection.

Emerging experimental observations suggest that SAC may reduce cellular expression of IL-6 and MMPs.

IL-6 is one of the major inflammatory cytokines elevated in:

• Alzheimer's disease
• Parkinson's disease
• Age-related cognitive impairment

Excessive IL-6 signaling can promote:

• Chronic microglial activation
• Astrocyte reactivity
• Synaptic degeneration
• Impaired long-term potentiation (LTP)

By reducing IL-6 production, SAC may help create a more favorable environment for neuronal survival and synaptic communication.

Matrix metalloproteinases, particularly MMP-2 and MMP-9, are involved in extracellular matrix remodeling and blood-brain barrier integrity.

Excessive MMP activity has been associated with:

• BBB leakage
• Neuroinflammation
• Amyloid pathology
• Cognitive impairment

Suppression of MMP activity may help preserve neuronal microenvironments and reduce inflammatory injury.

Astrocytes and microglia are key regulators of neuroinflammation.

In Alzheimer's disease, activated glial cells produce:

• IL-6
• TNF-α
• Reactive oxygen species
• MMPs

These mediators further amplify neuronal damage.

If SAC delivered through nasal pathways reaches brain tissue and modulates inflammatory signaling, it may promote a shift from a pro-inflammatory state toward a neuroprotective phenotype.

Such effects could support:

• Synaptic maintenance
• Neuronal survival
• Improved neural network function

The hippocampus is highly sensitive to inflammatory stress.

Chronic inflammation can impair:

• Learning capacity
• Memory consolidation
• Executive function
• Spatial navigation

By reducing neuroinflammatory mediators, SAC may potentially:

• Enhance synaptic plasticity
• Support long-term potentiation
• Improve neuronal communication
• Preserve hippocampal function

These mechanisms could theoretically contribute to improvements in:

• Memory retention
• Cognitive processing speed
• Attention
• Learning performance

Several pathological processes in Alzheimer's disease involve calcium dysregulation and inflammatory signaling.

Potential benefits of intranasal SAC may include:

• Reduction of IL-6-mediated neuroinflammation
• Suppression of MMP-induced tissue injury
• Protection of blood-brain barrier integrity
• Support of neuronal calcium homeostasis
• Improvement of mitochondrial function
• Enhancement of neuronal survival pathways

Collectively, these effects could theoretically slow progression of neurodegenerative changes.

Although the proposed mechanisms are biologically plausible, direct evidence remains limited. Future studies should investigate:

1. Brain uptake of SAC following intranasal administration.
2. Effects on hippocampal IL-6 and MMP expression.
3. Influence on astrocyte and microglial activation.
4. Effects on learning and memory in Alzheimer's animal models.
5. Impact on amyloid-beta and tau pathology.
6. Long-term safety and pharmacokinetics.

Randomized clinical studies will ultimately be required to determine whether SAC nasal spray can provide meaningful cognitive benefits in humans.

Neuroinflammation is a major driver of cognitive decline and neurodegenerative disease. Preliminary observations indicating that SAC reduces IL-6 and MMP expression suggest a potential role as a neuroinflammatory modulator. Because intranasal administration can provide direct access to the brain through olfactory and trigeminal pathways, SAC nasal spray may represent a promising strategy for supporting neuronal health, preserving hippocampal function, and enhancing memory and cognition. While these proposed benefits remain hypothetical and require rigorous experimental validation, the combination of anti-inflammatory activity and direct brain delivery provides a compelling rationale for future investigation of SAC as a novel therapeutic approach for cognitive impairment and Alzheimer's disease.